Lantern Pharma Survey on Use of Healthcare Data for A.I. and Therapy Development
In October 2019, Lantern Pharma commissioned a third-party administrator to electronically survey 1,054 adults over the age of 18 living in the United States. We asked questions relating to the use of patient and healthcare information as data points for the development of cancer treatments using A.I. (artificial intelligence).
To receive the results for the Survey on the U.S. Public Sentiment Towards Use of Patient and Healthcare Datain A.I. and for Cancer Drug Development, please make an email request to email@example.com
Let’s start a conversation about the future of drug development.
We are a biotech pharma at the intersection of Artificial Intelligence, genomics, and oncology drug development.